Beijing News (reporter Zhang Xiulan) The news that GlaxoSmithKline (China) Investment Co., Ltd. cancelled the "Drug Business License" has aroused industry concern. On June 29, GlaxoSmithKline said in a reply to the Beijing News reporter that GlaxoSmithKline Group has registered and established GlaxoSmithKline Enterprise Management Co., Ltd. in 2020, which is responsible for the import and distribution of GlaxoSmithKline Group's imported products in China, and has obtained the "Drug Business License" in May this year.
The incident stemmed from a notice issued by the Shanxi Provincial Centralized Bidding and Procurement Network on June 28: GlaxoSmithKline (China) Investment Co., Ltd.'s "Drug Business License" has been cancelled and will no longer be responsible for any imported drug agency and bidding.
On issues such as the ownership of its imported drug agency work, on June 29, GlaxoSmithKline said in a reply to the Beijing News reporter that GlaxoSmithKline Group registered and established GlaxoSmithKline Enterprise Management Co., Ltd. in Pudong, Shanghai in March 2020, responsible for the import and distribution of GlaxoSmithKline Group's import products in China, and the company obtained the "Drug Business License" in May 2021.
The move is also believed to echo GlaxoSmithKline's recent strategic moves. Last week, GlaxoSmithKline unveiled plans to split its consumer healthcare business with Pfizer into a separate company by the middle of next year, with GlaxoSmithKline focusing more on prescription drugs and vaccines in the future. In the domestic market, GlaxoSmithKline's consumer health care business is mainly attributed to Sino-US SKline.
Proofreading Lucy
![Interview with GlaxoSke Chishin: With core competitiveness, we will steadily develop the Chinese market[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)